Vyant Bio, Inc. - VYNT STOCK NEWS

Vyant Bio has announced its decision to voluntarily delist from The Nasdaq Capital Market, effective around May 14, 2023. This decision followed a thorough review by its Board of Directors, aiming to reduce operational costs and refocus resources on potential strategic alternatives or an orderly wind down if necessary. The company has filed a Form 25 with the SEC and will also file a Form 15 to suspend its reporting obligations. Vyant Bio adopted a Cash Preservation Plan to manage expenses, including workforce reductions and deferring clinical activities. Post-delisting, shares will trade on the OTC Pink Open Market under the symbol VYNT.

Vyant Bio, a biotechnology firm focused on neurodevelopmental and neurodegenerative disorders, announced significant changes on February 3, 2023. The company's Board of Directors approved a reduction in force to conserve cash while exploring strategic alternatives, guided by LifeSci Capital. As part of this transition, CEO John A. Roberts and CSO Robert T. Fremeau stepped down. CFO Andrew D. C. LaFrence has been appointed as the new CEO. The Board believes the current stock price does not reflect the company's intrinsic value, prompting the search for strategic options or a potential wind down.

Vyant Bio (Nasdaq: VYNT) announced it has engaged LifeSci Capital as its financial advisor to explore strategic alternatives aimed at enhancing shareholder value. The company is simultaneously participating in BIO’s One-on-One Partnering event during the JP Morgan Healthcare Conference. CEO Jay Roberts highlighted the progress in its drug discovery strategy targeting neurodevelopmental and neurodegenerative diseases, but indicated the need for strategic considerations moving forward. There is no assurance that this review will result in any changes to current plans.

Vyant Bio has made significant strides in drug discovery for neurodevelopmental disorders, presenting findings at the Rett Nanosymposium on November 16, 2022. The company identified a therapeutic candidate for Rett syndrome that shows promise for clinical trials. Their innovative CNS drug discovery platform utilizes human-derived organoid models, machine learning, and scaled biology for drug target validation. Additionally, Vyant is advancing donepezil as a repurposed treatment for Rett syndrome, with a clinical trial application submitted in Australia.

Vyant Bio, Inc. (Nasdaq: VYNT) announced it has regained compliance with Nasdaq's minimum bid price requirement. On November 16, 2022, Nasdaq notified the company that its shares maintained a closing bid price of at least $1.00 for ten consecutive business days. This milestone is significant for maintaining its listing status on the Nasdaq Capital Market. Vyant Bio focuses on innovative drug discovery for neurodevelopmental and neurodegenerative disorders using organoid models and machine learning technologies.

Vyant Bio (VYNT) reported Q3 2022 highlights, including a cash balance of $9.4 million as of September 30, 2022. The company completed the sale of its vivoPharm subsidiary for $5.5 million, netting approximately $4.4 million post-expenses. This sale enables the company to fund operations through at least 2023. Vyant Bio is advancing its CNS drug discovery platform and preparing for a clinical trial for VYNT-0126 in adult Rett patients. A virtual R&D Day is scheduled for early December to discuss ongoing research.

Vyant Bio (Nasdaq: VYNT), a biotechnology company, presented key findings from its CNS drug discovery platform at the CDKL5 Forum on November 7-8, 2022. The platform utilizes patient-derived organoid models to identify promising drug candidates for CDKL5 deficiency disorder (CDD), a rare neurodevelopmental condition. Key insights include the development of a cortical organoid model, identification of therapeutic targets, and collaborative efforts leading to a novel receptor discovery. CEO Robert T. Fremeau Jr. emphasized the platform's potential in discovering therapies for complex CNS disorders.

Vyant Bio (Nasdaq: VYNT) is set to participate in Neuroscience 2022, scheduled for November 12-16 at the San Diego Convention Center. The company will present two papers on Rett syndrome and a poster on CDKL5 deficiency disorder. The presentations will highlight a repurposed drug aimed at Rett syndrome, with clinical trials expected in 2023, and the identification of novel therapeutic candidates for CDKL5. With its advanced drug discovery platform, Vyant Bio focuses on treating neurodevelopmental and neurodegenerative disorders.

Vyant Bio (Nasdaq: VYNT) announces its partnership with the International Rett Syndrome Foundation to host a local viewing party for the 3rd Annual Raise a Glass for Rett Gala on November 12, 2022, at the University of California, San Diego Faculty Club. This event aims to raise awareness and support for families affected by Rett Syndrome, a rare genetic disorder. The gala will broadcast live from New York City, with over $400,000 raised in prior events for research and support. Tickets for the San Diego event can be found on Vyant's website.